Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib and MK-2206 vs mFOLFOX in Metastatic Pancreatic Cancer
NCT01658943Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2012
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib, MK-2206 in pancreatic adenocarcinoma (PDAC), sponsored by National Cancer Institute. Started Aug 2012; status: completed.
02
Drugs
selumetinibMK-2206
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01658943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01658943.